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a  b  s  t  r  a  c  t
Hericium  erinaceus  (H.  erinaceus)  has  a long  history  of  usage  in  traditional  Chinese  medicine
for  the treatment  of  gastric  disorders.  Recently,  it has  become  a  well-established  candidate
in causing  positive  brain  and  nerve  health-related  activities  by inducing  nerve growth  fac-
tor  (NGF)  from  its  bioactive  ingredient,  erinacine  A. This  active  compound,  which  exists
only  in fermented  mycelium  but not  in  its  fruiting  body,  increases  NGF  levels  in  astroglial
cells  in  vitro  as  well  as  catecholamine  and NGF  levels  in  vivo.  With  increasing  recognition
of  erinacine  A  in  H. erinaceus  (EAHE)  mycelium  improving  neurodegenerative  diseases,
numerous  products  are  being  marketed  based  on these  functional  claims.  To  our  knowl-
edge,  there  have  been  no  reports  on  the mutagenicity  of  EAHE  prior  to this  paper.  Hence,
the  present  study  was  undertaken  to determine  the  mutagenicity  and  genotoxicity  effects
of EAHE  mycelium  conducted  in  three  standard  battery  of  tests  (reverse  mutation,  chromo-
somal aberration,  and  micronuclei  tests)  according  to the  latest  guidelines  in  order to  meet
all international  regulatory  requirements  and  provide  information  on  the  safety  of this  new
and promising  natural  remedy.  Our  results  have  indicated  that  EAHE  mycelium  did not sig-
niﬁcantly increase  the  number  of  revertant  colonies  in the bacterial  reverse  mutation  test
nor induce  higher  frequency  of  aberrations  in the chromosome  aberration  test.  Moreover,
no statistically  signiﬁcant  EAHE  mycelium-related  increase  was  observed  in the  incidence  of
reticulocytes per  1000  red  blood  cells  and  micronucleated  reticulocytes  per  1000  reticulo-
cytes. In conclusion,  the  three  standard  battery  of  tests  suggested  that  EAHE  mycelium  was
devoid  of  mutagenicity  and genotoxicity  in the tested  doses  and  experimental  conditions.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  underhiazolyl blue tetrazolium bromide
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1. Introduction
Senile dementia, such as Alzheimer’s disease, is a serious
global public health crisis as there is no effective therapy
for  it currently. Neurohealth, is thus a major concern of the
predicted  Silver Tsunami – the growing wave of people who
will  reach the age of 65 over the next two decades and may
be  affected by geriatric cognitive disorders – which will
greatly impact society in the next 40 years as the number
of  dependent older people is estimated to increase three-
fold,  from 101 million in 2010 to 277 million in 2050 [1].
It  has been shown that dysregulation of nerve growth fac-
tor  (NGF) signaling is linked to early stages of neurological
diseases [2,3]. The absence of NGF has shown to cause an
Alzheimer-like symptom in the brains of 15 to 17 months
old  anti-NGF transgenic mice [4], but such symptoms could
be  ameliorated by the intranasal administration of NGF in
transgenic  anti-NGF mice (AD11 mice) that have a progres-
sive  neurodegenerative phenotype resembling Alzheimer’s
disease [5]. Although there is a widespread interest in NGF
as  a potential therapeutic agent, the high molecular weight
of  NGF makes it unable to cross the blood–brain barrier.
Alternatively, there are new approaches being developed
which focus on low-molecular weight compounds that can
cross  the brain–blood and promote NGF biosynthesis [6].
Hericium  erinaceus (H. erinaceus), a culinary and medic-
inal  mushroom, has been extensively studied for its
neurohealth properties. It has a long history of usage
in  traditional Chinese medicine for the treatment of
digestive diseases [7], but recently, it has also been
reported to exhibit other various pharmacological activ-
ities,  including anti-cancer, anti-microbial, anti-diabetic,
anti-hypertensive, anti-fat deposit, antioxidant, gastro-
protective, neuro-protective, immuno-modulating, and
wound-healing properties [8–17]. Among these health-
beneﬁcial roles, its role in protecting and stimulating nerve
cells,  however, is the most sought after characteristic out
of  all the other edible mushrooms with medicinal value.
Extracts of H. erinaceus, such as hericenones C–H [18,19]
and erinacines A–I [20–23], have all shown to induce the
expression of NGF in cultured rodent astrocytes. Erinacine
A,  the main representative of the compounds in H. eri-
naceus extracts, has demonstrated epinephrine-stronger
NGF-inducing activities in vitro and in vivo [24]. Further-
more, such NGF stimulating effects have been augmented
by the increased availability of the active compound (up to
8  mg/kg body weight) [24], and it has also been achieved
via  oral administration [25]. Hence, there is potential in
developing H. erinaceus enriched with erinacine A (EAHE)
as  an ingredient in medicinal foods or products to help in
the  reduction or even the prevention of age-related neu-
rodegenerative diseases.
To  our knowledge, there have been no reports on
the mutagenicity of H. erinaceus prior to this paper. Fur-
thermore, mushroom mycelium has an identity distinct
from mushrooms, which are categorized into two speciﬁc
classes of compounds: hericenones and erinacines, where
they  can only be extracted from the fruit body and the
cultured mycelium, respectively. Our previous 28-day
sub-chronic toxicity test in Sprague-Dawley rats showed
no  evidence of systemic toxicity attributable to EAHEs 1 (2014) 1195–1201
administration [26]. It was  estimated that NOAEL (no
adverse effect level) of EAHE mycelium is greater than
3  g/kg of body weight/day, which is 171.4 times the
recommended daily intake for humans (1.05 g/60 kg of
body  weight/day). Additional research on EAHE, including
an  assessment of its mutagenic and carcinogenic potential,
however, should be included to further support the safety
of  its consumption. Evaluation of the genotoxic properties
is  important in the context of European Union and interna-
tional  legislations aiming to protect human health. For an
adequate  assessment of the genotoxic potential, three end-
points  need to be considered: gene mutations, structural
chromosome aberrations, and numerical chromosome
aberrations. Hence, the present study was undertaken
to determine the mutagenicity and genotoxicity effects
of  EAHE mycelium conducted in three standard battery
of  tests (reverse mutation, chromosomal aberration, and
micronuclei tests) according to the latest guidelines in
order  to meet all international regulatory requirements
and provide information on the safety of this new and
promising natural remedy.
2.  Materials and methods
2.1.  Preparation, identiﬁcation, and quantiﬁcation of
EAHE
H.  erinaceus (BCRC 35669) purchased from Biore-
sources Collection and Research Center (BCRC) in Food
Industry Research and Development Institute (Hsinchu,
Taiwan) were maintained and cultivated according to the
method  described earlier [27]. The proximate composi-
tion analysis, which includes ash, total proteins, lipids,
and  carbohydrates of the freeze-dried mycelia, was deter-
mined  according to ofﬁcial Association of Ofﬁcial Analytical
Chemists (AOAC) methods [28]. The 5 mg/g active erinacine
A  content in the mycelia was  quantiﬁed and qualiﬁed via
high  performance liquid chromatography (HPLC) accord-
ing  to our previous published protocol [27]. In brief, a
COSMOSIL 5C18-AR-II (250 × 4.6 mm;  particle size 5 m;
Nacalai USA, Inc.) column with a column temperature of
40 ◦C was employed, and a solvent system consisting of
methanol (A) and 2.0% acetic acid in water (B) was used
for  HPLC elution. Retention time of erinacine A detected by
UV  at 340 nm was approximately ∼17 min  at a ﬂow rate of
1.0  mL/min.
2.2.  Animals and husbandry
7-week  old male ICR mice used for the in vivo eryth-
rocyte micronucleus test were procured from BioLASCO
Taiwan Co., Ltd and were utilized after a week of acclima-
tization and quarantine. ICR mice were housed in groups
of  ﬁve in polypropylene cages with absorbent hardwood
bedding (Beta Chip; Northeastern Products Corp, USA). The
animals  were maintained in a well-ventilated room (10–15
air  changes/h) under an ambient temperature of 22 ± 3 ◦C
and  55 ± 15% relative humidity on a 12:12 h light regime,
and  they were provided with standard rodent diet (MF-
18;  Oriental Yeast Co., Ltd, Tokyo, Japan) as well as puriﬁed
water  ad libitum. All husbandry conditions were conformed
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o the guidelines set forth by the National Institutes of
ealth  (NIH) for the care and use of laboratory animals,
nd were carried out under Good Laboratory Practice (21
FR  Part 58). These protocols were approved by the Insti-
utional Animal Care and Use Committee (IACUC 101-11e).
.3.  Bacterial reverse mutation test (Ames test)
This test was performed in accordance to the Organiza-
ion for Economic Cooperation and Development (OECD)
uideline for the testing of chemicals no. 471 [29] with the
acterial  reverse mutation test. EAHE at doses of 0.3125,
.625, 1.25, 2.5, and 5 mg/plate were tested for gene muta-
ion  using Salmonella typhimurium strains TA98, TA100,
A102, TA1535, and TA1537 (MolTox Inc., USA), both in the
resence  (0.5 ml  S9 mix) and absence (0.5 ml  of 0.2 M phos-
hate  buffer, pH 7.4) of metabolic activation. The S9 mix
f  aroclor 1254-induced rat liver homogenate was freshly
repared before each test as described by the previous
tudy [30]. Dimethyl sulfoxide was used as the diluent for
AHE  and as the negative control. Positive controls used
ere  4-nitroquinoline-N-oxide, sodium azide, mitomycin
,  9-aminoacridine, 2-aminoanthracene, benzo[a]pyrene,
nd 2-aminoﬂuorene (Sigma-Aldrich, MO,  USA). In brief,
00  l of bacterial culture was exposed to different doses
f  EAHE in both the presence and absence of metabolic
ctivation before adding it to 2 ml  of molten top agar
ontaining 0.5 mM of histidine/biotin. The mixture was
ubsequently poured on the surface of minimal glucose
gar  plates which were then incubated at 37 ◦C for 48 h
rior  to revertant colonies counting. All testing groups were
et  up in triplicates. A positive result was determined by
he  dose dependent increase and the two-fold increase in
evertant  numbers over the negative control.
.4. In vitro chromosome aberration test
This test was conducted in Chinese Hamster Ovary
CHO-K1) cells according to the OECD Guideline for the
esting  of chemicals no. 473 [31] with the in vitro mam-
alian chromosome aberration test. As the amount of
recipitation recorded for EAHE was at 5 mg/ml, dose lev-
ls  of 2.5, 1.25, and 0.625 mg/ml  were selected and exposed
o  the CHO-K1 cells (BCRC 60006) in the presence and
bsence of a metabolic activation system derived from rat
iver  S9 mix  [30]. The cells were maintained in Ham’s/F-12
edium at 5% CO2 and 37 ◦C. Two independent exper-
ments were performed in duplicate. In the temporary
reatment, CHO-K1 cells were exposed to EAHE for 3 h
ollowed by a recovery period of 17 h, with and without
etabolic activation. In the continuous treatment, cells
ere  incubated for 20 h in the absence of metabolic acti-
ation.  At the end of the treatment, parallel experiments
ere conducted where cells were either determined by
TT  assay for cell growth inhibition or prepared for chro-
osome observation. In brief, cells were treated with
.1  g/ml demecolcine solution (Sigma-Aldrich, MO,  USA)
or  4 h prior to harvesting. Cell pellets of each treatment
roup were resuspended in 0.075 M KCl solution and were
xed  using methanol/glacial acetic acid at a ratio of 3:1
/v.  After ﬁxation, cells were applied to a glass slide,s 1 (2014) 1195–1201 1197
stained with Diff Quik (Sysmex Corporation, Kobe, Japan),
mounted with Neo-Mount Anhydrous Mounting Medium,
and  then microscopically evaluated (at least 100 well-
spread metaphases/dish). 80 g/ml of cyclophosphamide
(Sigma-Aldrich, MO,  USA) with metabolic activation and
6  g/ml of mytomycin C without metabolic activation were
used  as positive controls. EAHE is considered to damage
chromosomes in CHO-K1 cells when the frequency of aber-
rant  cells is >3% with a dose dependent increase. Abnormal
cells were determined by the observation of chromosome
gap (G), chromosome break (B), chromosome dicentric (D),
chromosome ring (R), chromatid gap (g), chromatid break
(b),  and chromatid exchange (e).
2.5. In vivo erythrocyte micronucleus test
This test was carried out using the OECD Guideline for
the  testing of chemicals #474 [32] with the mammalian
erythrocyte micronucleus test. EAHE at dose levels of 1.25,
2.5,  and 5 g/kg BW (20 ml/kg by gavage) were evaluated for
its  potential to induce micronuclei in the peripheral blood
lymphocytes of male ICR mice. The doses were selected
according to the results of the single-dose acute study
and  were given once for the study. Each experimental
group (low, mid, and high dose) contained ﬁve male mice.
These  mice received the vehicle (distilled water) by gavage
and  were administrated with 80 g/ml cyclophosphamide
(10 ml/kg) by intraperitoneal injection as negative and pos-
itive  controls, respectively. All experimental animals were
observed  once a day for signs of toxicity, mortality, and
morbidity until the completion of the treatment. The body
weight  of each animal was  recorded at the initiation of
the  treatment and prior to bone marrow sampling. Periph-
eral  blood samples (3 to 4 l) from tail vein were collected
at 48 h and 72 h after dosing and then applied to acridine
orange-coated slides for 3 to 4 h at room temperature. The
smear  samples were microscopically examined with a ﬂu-
orescent  microscope (Zeiss, Oberkochen, Germany) for the
number  of reticulocytes (orange-red signal), and reticu-
locytes that contained at least one positive micronucleus
(yellow-green signal). The results were expressed as the
frequency of reticulocytes per 1000 red blood cells and
micronucleated reticulocytes per 1000 reticulocytes.
2.6. Statistical analysis
All  values presented throughout this manuscript were
expressed as mean ± standard error of mean (SEM). Mean
differences between the control and the treatment groups
were  analyzed by one-way ANOVA followed by Duncan’s
test. Aberrant cells from each concentration were com-
pared to the negative control values using Chi-square
analyses. A value of p < 0.05 was considered to be statis-
tically signiﬁcant.
3.  Results and discussion
A  resurgence of interest in natural products is spread-
ing across many parts of the world currently as they are
thought to be new alternative medicines for conventional
therapies with fewer side effects. In East Asian countries
and more recently in the United States, intensive research
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Table  1
Ames  Test of EAHE mycelium using Salmonella typhimurium strains TA98, TA100, TA102, TA1535, and TA1537.
Dose (mg/plate) Number of revertants/plate (without S9 activation)
TA98 TA100 TA102 TA1535 TA1537
Negative controla 29 ± 3 148 ± 5 233 ± 9 20 ± 2 13 ± 2
Positive controlb 304 ± 8* 447 ± 19* 561 ± 15* 80 ± 10* 48 ± 5*
5 30 ± 5 149 ± 4 204 ± 13 26 ± 2 16 ± 1
2.5  32 ± 2 140 ± 13 216 ± 10 19 ± 6 15 ± 4
1.25  27 ± 3 144 ± 6 192 ± 15 27 ± 1 14  ± 3
0.625 30 ± 6 146 ± 6 207 ± 10 23 ± 4 14 ± 1
0.3125 25 ± 9 148 ± 12 225 ± 12 19 ± 4 13 ± 2
Number of revertants/plate (with S9 activation)
TA98 TA100 TA102 TA1535 TA1537
Negative controla 20 ± 1 160 ± 16 226 ± 13 17 ± 1 9 ± 2
Positive controlc 192 ± 17* 1103 ± 15* 1108 ± 15* 937 ± 8* 1089 ± 11*
5 26 ± 7 160 ± 2 211 ± 17 21 ± 3 11 ± 4
2.5  25 ± 2 169 ± 8 234 ± 19 22 ± 2 12 ± 2
1.25  26 ± 9 160 ± 4 228 ± 13 17 ± 3 11 ± 4
0.625 34 ± 6 155 ± 15 238 ± 12 19 ± 6 12 ± 2
0.3125 25 ± 5 164 ± 10 242 ± 13 15 ± 1 8 ± 3
Data were expressed as mean ± SD (n = 3).
* Two-fold or more increase in revertant numbers over the negative control.
a Dimethyl sulfoxide.
de, 0.4 
te; TA10b TA98: 4-nitroquinoline-N-oxide, 0.5 g/plate; TA100: sodium azi
0.4  g/plate; TA1537: 9-aminoacridine, 50 g/plate.
c TA98: benzo[a] pyrene, 4 g/plate; TA100: 2-aminoﬂuorene, 4 g/pla
TA1537:  9-aminoacridine, 50 g/plate.
has increasingly demonstrated the potential beneﬁcial
health properties of compounds extracted from mush-
rooms for the prevention and management of cancer
and other life-debilitating diseases. For such reasons, the
genotoxicity of culinary–medicinal mushrooms that are
used  by the general population should be warranted in
order  to identify the ingredients that pose mutagenic and
carcinogenic risks. To our knowledge, there have been no
reports  on the mutagenicity of H. erinaceus prior to this
paper.  Therefore, this is the ﬁrst report undertaken to
evaluate the genotoxicity of a standardized H. erinaceus
mycelium enriched with 5 mg/g erinacine A by using
the  Ames test, the chromosomal aberration test, and the
erythrocyte micronucleus test.
The Ames test is widely used as an initial screening
method to determine the mutagenic potential of newly dis-
covered  products since there is a high correlation between
the  positive responses in test mutagenicity and carcino-
genicity [33,34]. The proximate analysis and HPLC analysis
of  EAHE mycelium are shown in Table S1 and Fig. S1,
respectively. These results are in line with those previously
published [27]. Our initial test revealed no pronounced tox-
icity  on test strains at concentrations as high as 50 mg/ml
(5  mg/plate) (data not shown); therefore, we set this con-
centration as the upper limit of the tested dose range
and performed the Ames test with serial dilutions. The
results of in vitro bacterial genetic mutation assay are
summarized in Table 1. In all bacterial strains exposed
to  different doses of EAHE mycelium (5, 2.5, 1.25, 0.625,
and  0.3125 mg/plate) with the presence and absence of S9-
Mix  metabolic activators, the revertant colonies showed no
dose  dependency and were similar to those of negative con-
trol.  These ﬁndings suggest that EAHE mycelium displayed
no  mutagenicity, especially in S. typhimurium strains TA98,
TA100,  TA102, TA1535, and TA1597.g/plate; TA102: mitomycin C, 0.5 g/plate; TA1535: sodium azide,
2: benzo[a] pyrene, 4 g/plate; TA1535: 2-aminoanthracene, 4 g/plate;
Since the Ames test cannot detect chromosome aberra-
tions induced by chemicals [35], it has been recommended
to use in vitro tests as a minimum requirement for muta-
genicity testing [36]. According to the guidelines OECD 473
[31],  the highest dose used in the in vitro chromosome aber-
ration  test should be a concentration above the limit of
solubility to avoid false positive results. As the amount of
precipitation recorded for EAHE was  at 5 mg/ml, dose lev-
els  of 2.5, 1.25, and 0.625 mg/ml  were selected and exposed
to  the CHO-K1 cells (BCRC 60006) in the presence and
absence of a metabolic activation system derived from rat
liver  S9 mix  [30]. The cell proliferation of CHO-K1 in the 3 h
treatment  with the presence and absence of S9 activation
was  inhibited by <7.7% and <21.4%, respectively. Incuba-
tion  of these cells under the same condition for 20 h in the
absence  of S9 activation resulted in <34.3% decreases of
cell  growth (data not shown). As the highest concentration
showed a signiﬁcant reduction in the degree of conﬂuency,
such doses were then used for chromosome observation.
The validity of the tests was  observed in the incidence of
cells  having aberrant chromosomes, which was  0% to 1%
and  6.5% to 12.5% in negative groups and positive groups,
respectively (Table 2).
Neither  3 h nor 20 h EAHE mycelium treatments
induced higher frequency of aberrations that were signiﬁ-
cantly  different from negative controls (p > 0.05, Chi-square
test)  (Table 2). In summary, these data indicate that expo-
sure  to EAHE mycelium does not result in genetic damage
in  cultured mammalian cells under the test conditions.
The uptake of EAHE mycelium that resulted in chromo-
somal damage was further investigated by using the in vivo
erythrocyte micronucleus test in ICR mice since the in vivo
assay  takes into account whole animal processes, such as
absorption, distribution, metabolism, and excretion. Our
earlier  study on acute oral toxicity indicated that acute
I.-C. Li et al. / Toxicology Reports 1 (2014) 1195–1201 1199
Table 2
Chromosome aberration test of EAHE mycelium using CHO-K1 cells.
Dose S9-
Mixture
G  B D R g b e AFd
Short-term treatment (3 h)
Negative controla − 0 0 0 0 0 0 0 0/200
Positive controlb − 0 0 0 1 1 5 18 25/200*
2.5 − 0 0 0 1 0 0 3 4/200
1.25 − 0 0 0 0 0 0 0 0/200
0.625 − 0 0 0 0 1 0 0 1/200
Negative controla + 0 0 0 0 1 1 0 2/200
Positive controlc + 0 1 2 0 0 8 2 13/200*
2.5 + 0 0 0 0 0 1 0 1/200
1.25 + 0 0 0 0 0 0 1 1/200
0.625 + 0 0 0 0 0 1 0 1/200
Long-term treatment (20 h)
Negative controla − 0 0 0 0 0 0 0 0/200
Positive controlb − 0 0 2 0 2 5 11 20/200*
2.5 − 0 0 0 0 0 0 0 0/200
1.25 − 0 0 0 0 0 0 0 0/200
0.625 − 0 0 0 0 0 0 0 0/200
G: chromosome gap; B: chromosome break; D: dicentric; R: ring;
g: chromatid gap; b: chromatid break; e: chromatid exchange.
* Statistically signiﬁcant (p < 0.05, Chi-square test) when compared to
the  control group.
a Ham’s/F-12 Culture medium.
b 6 M mitomycin C.
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Fig. 1. Effects of EAHE on the (A) body weight, incidence of (B) reticu-
locytes (RETs), and (C) micronucleated reticulocytes (MN-RETs) in ICR
mice (n = 25). Distilled water and cyclophosphamide (0.05 g/kg) were
served as negative (NC) and positive controls (PC), respectively. Data
*c 80 M cyclophosphamide.
d Aberration frequency: Number of cells with chromosome aberration
n 200 metaphase cells (n/200).
ral LD50 of EAHE mycelium was greater than 5 g/kg (data
ot  shown). Hence, doses of 1.25 g/kg (low dose), 2.5 g/kg
mid  dose) and 5 g/kg (high dose) were selected for this
tudy, whereas distilled water and cyclophosphamide were
erved  as negative and positive controls, respectively. Dur-
ng  the 72-h post-treatment, EAHE at all tested doses (1.25,
.5,  and 5 g/kg) did not induce any symptoms of toxicity,
orbidity, or mortality in all mice (n = 25). Regarding body
eight,  no signiﬁcant difference was observed between the
ontrol  and treated groups (p > 0.05, one-way ANOVA fol-
owed  by Duncan’s test) (Fig. 1a). The rate of reticulocytes
ccurrence per 1000 red blood cells (RBC) was 44.8 ± 1.9%
nd  46.4 ± 1.7% in negative control groups at 48-h and 72-h
ost-treatment, respectively (Fig. 1b). Results showed that
yclophosphamide effectively induced myelosuppression
37] by signiﬁcantly decreasing the rates in the positive
ontrol groups (p < 0.05, one-way ANOVA followed by Dun-
an’s  test) after dosing, but no signiﬁcant differences were
oted  in all EAHE testing groups when compared to the
egative control (p > 0.05, one-way ANOVA followed by
uncan’s  test) (Fig. 1b).
On  the other hand, the incidence of micronucleated
eticulocytes in the peripheral blood per 1000 reticulo-
ytes was 0.8 ± 0.4% and 0.0 ± 0.0% in negative control
roups at 48-hr and 72-hr post-treatment, respectively
Fig. 1c). The positive control group had a mean fre-
uency of 22.4 ± 1.3% and 19.6 ± 1.6% at 48-h and 72-h
ost-treatment, respectively, which were statistically sig-
iﬁcant  increases compared to the negative control groups
p  < 0.05, one-way ANOVA followed by Duncan’s test).
t  48-h post-treatment, the EAHE treated groups had
.0  ± 0.3%, 0.8 ± 0.4%, and 1.2 ± 0.6% micronucleated retic-
locytes  per 1000 reticulocytes at low, mid, and high testwere expressed as mean ± SEM. Statistically signiﬁcant (p < 0.05, one-
way ANOVA followed by Duncan’s test) when compared to the control
group.
dose levels, respectively (Fig. 1c). Similar trends were also
observed  after 72-h treatment. These values were not sta-
tistically  signiﬁcant, and hence did not demonstrate any
signs  of toxicity with the administration of EAHE mycelium
in  the mouse erythrocyte micronucleus assay. The results
of  the in vivo assay were thus consistent with those of the
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[
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in vitro mutagenicity test, which strongly suggest that con-
sumption  of standardized EAHE does not pose genotoxic
hazards to individuals.
4.  Conclusion
This pioneering work showed that through use of the
three-core test system for genetic damage, 5 mg/g eri-
nacine A-enriched H. erinaceus mycelium was devoid of
its  genotoxic effects under our experimental conditions.
Our ﬁndings support that the risk of EAHE having geno-
toxic  activity is low. Additional research on EAHE, including
a  randomized controlled clinical trial, may  be included in
future  studies to further support the safety of its consump-
tion.
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